In Silico Drug Design: Finally Ready For Prime Time?
Advances in computational power and in the application of quantum mechanics to drug modeling are rekindling interest in in silico drug design. The prize is a steep reduction in the cost of discovery and an increase in the quality of lead candidates.
You may also be interested in...
Artificial intelligence won’t transform pharma R&D, at least not anytime soon. But it is already impacting health care delivery and clinical trials.
The Fremont, California-based company has developed a computer-driven discovery platform that can model drug-protein interactions with unparalleled accuracy but can also generate synthetic pathways for its drug candidates.
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.